Pacific Biosciences Of California (PACB) Total Current Liabilities (2010 - 2026)

Pacific Biosciences Of California has reported Total Current Liabilities for 17 years, with the latest figure at $68.8 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 15.15% year-over-year to $68.8 million in Q2 2026; TTM through Jun 2026 was $68.8 million, a 15.15% increase from a year earlier, with the FY2025 full-year figure at $72.8 million, up 9.85% from the prior year.
• Total Current Liabilities was $68.8 million for Q2 2026 at Pacific Biosciences Of California, up from $65.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $271.4 million in Q2 2023, with the low at $59.8 million in Q2 2025.
• Average Total Current Liabilities over 5 years is $110.0 million, with a median of $72.9 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 335.46% in 2023, then sank 72.54% in 2024.
• Over 5 years, Total Current Liabilities stood at $263.3 million in 2022, then slumped by 63.91% to $95.0 million in 2023, then plunged by 30.23% to $66.3 million in 2024, then advanced by 9.85% to $72.8 million in 2025, then decreased by 5.53% to $68.8 million in 2026.
• The last three Total Current Liabilities figures came in at $68.8 million (Q2 2026), $65.4 million (Q1 2026), and $72.8 million (Q4 2025), per Business Quant data.